title: Pretreatment of cisplatin in recipients attenuates post-transplantation pancreatitis in murine model.
abstract: Pancreas transplantation is the definite treatment for type 1 diabetes that enables the achievement of long-term normoglycemia and insulin independence. However Post-Transplantation Pancreatitis (PTP) due to ischemia reperfusion (IR) injury and preservation is a major complication in pancreas transplantation. Owning the potential anti-inflammatory effect of Cisplatin (Cis) in liver IR injury, we have examined if Cis could attenuate PTP using a murine model. We found that Cis is able to prevent inflammatory response in PTP. Pretreatment of Cis in recipient mice reduce the impairments of the grafts and hyperamylasimea in the recipients. We documented that the protective mechanism of Cis in PTP involves improvement of microcirculation, reduction of the mononuclear cellular infiltration and apoptosis, suppression of inflammatory cytokine-cascade and inhibition of translocation of high-motility group box protein-1 (HMGB-1) from nucleus to cytoplasm. In short, our study demonstrated that pretreatment of Cis in recipients may reduce the onset of PTP in pancreas transplantation.
authors.affiliation: Division of Hepatobiliary and Pancreatic Surgery, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China.
authors.forename: Sheng
authors.initials: S
authors.lastname: Yan
authors.forename: Yuan
authors.initials: Y
authors.lastname: Ding
authors.forename: Fei
authors.initials: F
authors.lastname: Sun
authors.forename: Zhongjie
authors.initials: Z
authors.lastname: Lu
authors.forename: Liang
authors.initials: L
authors.lastname: Xue
authors.forename: Xiangyan
authors.initials: X
authors.lastname: Liu
authors.forename: Mingqi
authors.initials: M
authors.lastname: Shuai
authors.forename: Chen
authors.initials: C
authors.lastname: Fang
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Hui
authors.initials: H
authors.lastname: Cheng
authors.forename: Lin
authors.initials: L
authors.lastname: Zhou
authors.forename: Ming H
authors.initials: MH
authors.lastname: Zheng
authors.forename: Shusen
authors.initials: S
authors.lastname: Zheng
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D006084:Graft Rejection / Q000517:prevention & control*; D024243:HMGB1 Protein / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008833:Microcirculation; D008856:Microscopy, Fluorescence; D010179:Pancreas / Q000098:blood supply / Q000187:drug effects / Q000648:ultrastructure; D016035:Pancreas Transplantation; D010195:Pancreatitis / Q000209:etiology / Q000517:prevention & control*; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control*; D011292:Premedication; D021381:Protein Transport / Q000187:drug effects; D013047:Specific Pathogen-Free Organisms
chemical_list: D000893:Anti-Inflammatory Agents; D024243:HMGB1 Protein; D002945:Cisplatin